Company Overview - Immatics is building a global leadership position in TCR-based immunotherapies, leveraging proprietary platforms for target and T cell receptor discovery[3] - The company has validated its platforms through strategic collaborations with oncology-focused global leaders, including Amgen, Genmab, BMS, GSK, and MD Anderson Cancer Center[3] - Immatics had approximately $320 million in cash on its balance sheet after its NASDAQ debut, providing a cash runway of 3+ years[4] Pipeline Development - Immatics is advancing a proprietary pipeline of Adoptive Cell Therapies (ACT) and TCR Bispecifics, with four ACT programs in clinical development covering a broad range of solid cancers[3] - Two TCR Bispecifics programs with off-the-shelf availability are in advanced preclinical development[3] - The company's lead candidate for the IMA402 program is expected by YE 2020[7] - IND filing for IMA204 is planned for 2021[7] - IND filing for IMA401 is on track for YE 2021[7] - IMA301 program is on track for an IND filing in 2022[7] Technology and Targets - Immatics has prioritized over 200 pHLA targets using its XPRESIDENT® technology platform[9, 10, 16, 41] - The company's ACTengine® targets, such as MAGEA4/A8 (IMA201), MAGEA1 (IMA202), PRAME (IMA203), and COL6A3 exon 6 (IMA204), show high pHLA copy numbers per cell, ranging from 50-1,000[22, 26] Clinical Trial Updates - Initial data from IMA201, IMA202, and IMA203 ACTengine® trials showed very high frequencies of persisting circulating target-specific T cells, up to 45%, at the lowest infused dose[23] - Topline data for the multi-target pilot study IMA101 is planned to be presented at a scientific conference in 4Q 2020[63]